![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 9
Zeitschriftenartikel
Fischer, Luca 
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
Bornhäuser, Martin; Schliemann, Christoph; Schetelig, Johannes; Röllig, Christoph; Kramer, Michael; Glass, Bertram; Platzbecker, Uwe; Burchert, Andreas; Hänel, Mathias; Müller, Lutz P.; Klein, Stefan; Bug, Gesine; Beelen, Dietrich; Rösler, Wolf; Schäfer-Eckart, Kerstin; Schmid, Christoph; Jost, Edgar; Lenz, Georg; Tischer, Johanna; Spiekermann, Karsten ORCID: https://orcid.org/0000-0002-5139-4957; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Serve, Hubert; Stölzel, Friedrich; Alakel, Nael; Middeke, Jan Moritz; Thiede, Christian; Ehninger, Gerhard; Berdel, Wolfgang E. und Stelljes, Matthias
(2023):
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia.
In: JAMA Oncology, Bd. 9, Nr. 4: S. 519-526
ORCID: https://orcid.org/0000-0002-5139-4957; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Serve, Hubert; Stölzel, Friedrich; Alakel, Nael; Middeke, Jan Moritz; Thiede, Christian; Ehninger, Gerhard; Berdel, Wolfgang E. und Stelljes, Matthias
(2023):
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia.
In: JAMA Oncology, Bd. 9, Nr. 4: S. 519-526
Isfort, Susanne ORCID: https://orcid.org/0000-0002-2855-561X; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Wolf, Dominik und Brümmendorf, Tim H.
(2023):
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
In: Annals of Hematology, Bd. 102: S. 2741-2752
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-2855-561X; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Teichmann, Lino L.; Crysandt, Martina; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Kiani, Alexander; Göthert, Joachim R.; Illmer, Thomas; Schafhausen, Philippe; Al-Ali, Haifa Kathrin; Stegelmann, Frank; Hänel, Mathias; Pfeiffer, Tim; Giagounidis, Aristoteles; Franke, Georg-Nikolaus; Koschmieder, Steffen; Fabarius, Alice; Ernst, Thomas; Warnken-Uhlich, Mareille; Wolber, Uta; Kohn, Denise; Pfirrmann, Markus ORCID: https://orcid.org/0000-0002-8948-0690; Wolf, Dominik und Brümmendorf, Tim H.
(2023):
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
In: Annals of Hematology, Bd. 102: S. 2741-2752
[PDF, 1MB]
Hirt, Carsten; Hoster, Eva; Unterhalt, Michael; Hänel, Mathias; Prange-Krex, Gabriele; Forstpointner, Roswitha; Florschütz, Axel; Graeven, Ullrich; Frickhofen, Norbert; Wulf, Gerald; Lengfelder, Eva; Lerchenmüller, Christian; Schlag, Rudolf; Dierlamm, Judith; Fischer von Weikersthal, Ludwig; Ahmed, Asima; Harich, Hanns-Detlev; Rosenwald, Andreas; Klapper, Wolfram; Dreyling, Martin; Hiddemann, Wolfgang und Herold, Michael
(2021):
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients. A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
In: HemaSphere, Bd. 5, Nr. 7, e600
Brioli, Annamaria ORCID: https://orcid.org/0000-0002-4072-7592; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Pfirrmann, Markus; Hänel, Mathias; Schwarzer, Andreas Christoph; Prange-Krex, Gabriele; Fabisch, Christian; Knop, Stefan; Illmer, Thomas; Krammer-Steiner, Beate; Hochhaus, Andreas; Lilienfeld-Toal, Marie von und Mügge, Lars-Olof
(2. März 2020):
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
In: Journal of cancer research and clinical oncology, Bd. 146, Nr. 3: S. 749-759
ORCID: https://orcid.org/0000-0002-4072-7592; Manz, Kirsi ORCID: https://orcid.org/0000-0002-7740-4076; Pfirrmann, Markus; Hänel, Mathias; Schwarzer, Andreas Christoph; Prange-Krex, Gabriele; Fabisch, Christian; Knop, Stefan; Illmer, Thomas; Krammer-Steiner, Beate; Hochhaus, Andreas; Lilienfeld-Toal, Marie von und Mügge, Lars-Olof
(2. März 2020):
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
In: Journal of cancer research and clinical oncology, Bd. 146, Nr. 3: S. 749-759
Schäfer, Niklas; Pröscholdt, Martin; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Grauer, Oliver; Goldbrunner, Roland; Friedrich, Franziska; Rohde, veit; Ringel, Florian; Schlegel, Uwe; Sabel, Michael; Ronellenfitsch, Michael W.; Uhl, Martin; Grau, Stefan; Hänel, Mathias; Schnell, Oliver; Krex, Dietmar; Vajkoczy, Peter; Tabatabai, Ghazaleh; Mack, Frederic; Schaub, Christina; Tzaridis, Theophilos; Niessen, Michael; Kebir, Sied; Leutgeb, Barbara; Urbach, Horst; Belka, Claus; Stummer, Walter; Glas, Martin und Herrlinger, Ulrich
(2018):
Quality of life in the GLARIUS trial randomizing bevacizumab/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
In: Neuro-Oncology, Bd. 20, Nr. 7: S. 975-985
Herrlinger, Ulrich; Schäfer, Niklas; Steinbach, Joachim P.; Weyerbrock, Astrid; Hau, Peter; Goldbrunner, Roland; Friedrich, Franziska; Rohde, Veit; Ringel, Florian; Schlegel, Uwe; Sabel, Michael; Ronellenfitsch, Michael W.; Uhl, Martin; Maciaczyk, Jaroslaw; Grau, Stefan; Schnell, Oliver; Hänel, Mathias; Krex, Dietmar; Vajkoczy, Peter; Gerlach, Rüdiger; Kortmann, Rolf-Dieter; Mehdorn, Maximilian; Tüttenberg, Jochen; Mayer-Steinacker, Regine; Fietkau, Rainer; Brehmer, Stefanie; Mack, Frederic; Stuplich, Moritz; Kebir, Sied; Kohnen, Ralf; Dunkl, Elmar; Leutgeb, Barbara; Proescholdt, Martin; Pietsch, Torsten; Urbach, Horst; Belka, Claus; Stummer, Walter und Glas, Martin
(2016):
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O-6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
In: Journal of Clinical Oncology, Bd. 34, Nr. 14:
1611-U134
Proetel, Ulrike; Pletsch, Nadine; Lauseker, Michael; Müller, Martin C.; Hanfstein, Benjamin; Krause, Stefan W.; Kalmanti, Lida; Schreiber, Annette; Heim, Dominik; Baerlocher, Gabriela M.; Hofmann, Wolf-Karsten; Lange, Elisabeth; Einsele, Hermann; Wernli, Martin; Kremers, Stephan; Schlag, Rudolf; Müller, Lothar; Hänel, Mathias; Link, Hartmut; Hertenstein, Bernd; Pfirrmann, Markus; Hochhaus, Andreas; Hasford, Joerg; Hehlmann, Rüdiger und Saußele, Susanne
(Juli 2014):
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
In: Annals of Hematology, Bd. 93, Nr. 7: S. 1167-1176
[PDF, 985kB]
Hanfstein, Benjamin; Lauseker, Michael; Hehlmann, Rüdiger; Saussele, Susanne; Erben, Philipp; Dietz, Christian; Fabarius, Alice; Proetel, Ulrike; Schnittger, Susanne; Haferlach, Claudia; Krause, Stefan W.; Schubert, Joerg; Einsele, Hermann; Hänel, Mathias; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Pfirrmann, Markus; Hasford, Jörg; Hofmann, Wolf-Karsten; Hochhaus, Andreas und Müller, Martin C.
(2014):
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
In: Haematologica, Bd. 99, Nr. 9: S. 1441-1447
[PDF, 784kB]